Rejoni secures $25M to advance uterine healing hydrogel system toward FDA approval 🧬
Rejoni has closed a $25M financing round led by ClavystBio, with participation from Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta Group. The funding will advance Juveena, a hydrogel system designed to support endometrial healing following uterine trauma - a condition that can lead to infertility and is currently without a dedicated treatment option.
“Uterine health has been underserved for too long, and this financing puts us in a position to change that. We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved,”
— John Nealon, Chief Executive Officer, Rejoni
Aeroflow Health acquires Canopie to build a comprehensive maternal care platform 🤱
Aeroflow Health has acquired Canopie, a digital health company delivering virtual preventative care programmes for expecting and new mothers, with a focus on mental health and physical wellness. The deal builds on a partnership dating back to 2022 and gives Aeroflow's 1.7 million annual maternal health patients access to integrated mental health support alongside its existing lactation supplies, feeding support and perinatal education. Over a third of US counties are considered maternity care deserts, and nearly 60% of women with perinatal mental health conditions never receive a diagnosis.
“Supporting mothers through every stage of pregnancy, postpartum, and beyond has always been our vision, not just through products, but through education, clinical services, and personalized care. The addition of Canopie is a natural extension of that vision, strengthening our ability to address one of the most critical and underserved aspects of maternal health: mental wellness."
— Jennifer Jordan, EVP, Aeroflow Breastpumps
IVI RMA and Conceivable Life Sciences partner to deploy the first automated IVF lab in the US 🤖
IVI RMA Global, the world's leading fertility care network, has partnered with Conceivable Life Sciences to introduce AURA - the world's first automation-assisted robotic IVF laboratory platform - to a US clinic in 2027. AURA works alongside embryologists to replace hundreds of manual, operator-dependent steps with machine precision, with over 100 patients treated and live births already achieved in pilot studies. IVI RMA has also made a strategic investment in Conceivable as part of the agreement, with expansion across Europe, Latin America and the Middle East planned after the initial US deployment.
"By integrating innovative platforms such as AURA into our laboratory ecosystem, we are not only improving our patients' abilities to build families, but also demonstrating how advanced technology can complement the expertise of embryologists and clinicians,"
— Antonio Pellicer, Executive Chairman, IVI RMA Global
Imagion Biosystems raises AU$3.75M following FDA clearance for Phase 2 breast cancer imaging trial 🔬
The Australian medtech company has secured AU$3.75M (US$2.59M) in new capital off the back of FDA clearance for its IND application for a Phase 2 trial of MagSense, a novel imaging agent for HER2+ breast cancer. Patient recruitment is expected to begin later this year. The strong investor demand followed the FDA milestone, with the raise intended to fund commencement of the clinical trial.
“We are very pleased with the strong demand we saw from investors following our milestone achievement of receiving clearance from the FDA for our MagSense® imaging to proceed with the clinical trial. The successful submission of the IND represents a major technical and organizational accomplishment for the company. With this kind of shareholder support we can continue to advance our MagSense® molecular imaging technology and change how cancer is detected."
— Robert Proulx, Executive Chairman, Imagion Biosystems
Fraiya and Canon Medical Systems Europe partner to bring AI prenatal ultrasound support across Europe 🔊
London-based Fraiya has announced a strategic commercial collaboration with Canon Medical Systems Europe to introduce AI-powered prenatal ultrasound workflow support across selected European markets. Fraiya's software provides real-time image acquisition assistance, automated biometric measurements and scan completeness guidance during mid-trimester anomaly examinations. The technology has been developed with King's College London and Guy's and St Thomas' NHS Foundation Trust, with ongoing clinical evaluation through The Fraiya Study in the UK.
“We are delighted to collaborate with Canon Medical Systems Europe as we expand access to AI-powered prenatal ultrasound support. This collaboration brings together world-class ultrasound imaging and real-time AI workflow support to help address increasing clinical pressures facing prenatal ultrasound services today.”
— Reza Razavi, CEO, Fraiya
Mila raises $2.5M pre-seed to build intimate wellness into a daily self-care ritual 🌸
The female-founded, design-led intimate wellness brand has closed an oversubscribed $2.5M pre-seed round led by Mensch VC, with participation from Sticker Ventures and angel investors from Spotify, Dyson and Tetra Pak. Co-founders Kim Aviv and Ada Trujillo are positioning Mila at the intersection of beauty, wellness and intimacy - treating intimate care with the same design intent and ingredient quality as premium skincare. The raise will fund R&D, portfolio expansion and potential mass retail partnerships.
"This funding allows us to continue investing in research and development, expand our product portfolio, and bring more innovation into a category that has been underserved for far too long. We launched direct-to-consumer and are already in conversations with premium retail partners."
— Kim Aviv, Co-Founder, Mila
Intu Diagnostics raises €1.1M to advance lab-free HPV testing platform 🧪
The Leipzig-based diagnostics spinout from Fraunhofer Society has closed a €1.1M strategic bridge round backed by BSV Ventures and the Saxonian Development Bank, bringing total funding to over €3M. Intu's pocket-sized, power-free platform is designed to deliver molecular-level diagnostic quality without lab infrastructure - starting with HPV testing in women's health. Proceeds will go toward IP protection, pilot manufacturing and preparation for an upcoming seed round.
.png)
.png)
